Demand for lentiviral vectors market is estimated to surge at a CAGR of 11.4 % from 2022 to 2032 - Persistence Market Research - Seite 2

• Kits, a subgroup of the product segment, are widely used than reagents and consumables in terms of volume. The segment held 71.7% market share by value in 2021.
• Lentiviral vectors are mostly used for the treatment of cancer. The cancer segment, by indication, accounted for a market share of around 65.4% in 2021, which is the highest of all measured across the market.
• Academic and research institutes are focused on the development of various new treatment options based on lentiviral vectors for the treatment of various genetic, infectious, and other disorders. Thus, academic and research institutes held the highest market share of 49.1% by value in 2021.
• The North America lentiviral vectors market accounted for 35.5% of the global market share in 2021. This is due to the presence of major key players in this region.

Get customized report as per requirement: https://www.persistencemarketresearch.com/request-customization/33074

"Growing demand for lentiviral vectors, rise in prevalence of infectious diseases, and increasing burden of genetic disorders will drive growth of the lentiviral vectors market over the coming years," says an analyst of Persistence Market Research.

Market Competition

• Key suppliers of lentiviral vectors are focused on strategic collaborations and acquisitions to increase their market share value.
• SIRION Biotech, for example, established a collaboration with the Centre for Genomic Regulation in February 2022 to invent a new version of AAV vectors for type 1 and type 2 diabetic gene therapy.
• In April 2022, Charles River announced the acquisition of Explora BioLabs.

Get full access of report: https://www.persistencemarketresearch.com/checkout/33074

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the lentiviral vectors market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the products (kits [lentiviral packing systems, lentiviral expression systems, lentiviral promoter kits, and lentiviral fusion tags], reagents & consumables), indication (cancer, genetic disorders, infectious diseases, veterinary diseases, and others), and end user (biotechnology companies, pharmaceutical companies, contract research organizations (CROs), and academic and research institutes), across seven key regions of the world.